Ocugen, Inc. (OCGN) Stock Forecast

NASDAQ: OCGNAnalyst ratings, price target and estimates.

OCGN analyst forecast

as of October 18, 2026
Analyst consensus
Strong buy
4.83 / 5 from 6 analysts
Price target
$12.17
average of analyst targets
Upside to target
+1,459.8%
from the latest close
Next earnings
November 4, 2026
EPS estimate $-0.06
52-week range
$0.78 – $2.48

OCGN analyst ratings

6 analysts
Strong buy
583%
Buy
117%
Hold
00%
Sell
00%
Strong sell
00%

Number of analysts at each rating.

OCGN price target

Price $0.78Target $12.17
52-week low $0.7852-week high $2.48

The average of analyst 12-month price targets compared with the latest close and the 52-week range.

OCGN earnings per share estimates

Ocugen, Inc. EPS estimates
PeriodAverageLowHighYear agoGrowthAnalysts
Current quarter (Sep '26)−$0.05−$0.07−$0.04−$0.07+23.8%3
Current fiscal year (2026)−$0.24−$0.27−$0.18−$0.23−2.9%3
Next fiscal year (2027)−$0.25−$0.32−$0.18−$0.24−7.0%3

Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.

OCGN revenue estimates

Ocugen, Inc. revenue estimates
PeriodAverageLowHighGrowthAnalysts
Current quarter (Sep '26)$780,000$0$1.5M−55.5%5
Current fiscal year (2026)$5.0M$3.0M$6.1M+12.3%6
Next fiscal year (2027)$5.5M$0$12.0M+10.9%4

OCGN EPS: reported and forecast

Reported EPSEstimate (average; low–high)

Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.

OCGN revenue: reported and forecast

Reported revenueEstimate (average; low–high)

OCGN EPS estimate revisions

Ocugen, Inc. EPS estimate revisions
Period90 days ago60 days ago30 days ago7 days agoNowChange (90 d)Revisions (30 d)
Current quarter (Sep '26)−$0.05−$0.05−$0.05−$0.05−$0.050.0%0 up · 0 down
Current fiscal year (2026)−$0.22−$0.22−$0.27−$0.24−$0.24+6.0%1 up · 0 down
Next fiscal year (2027)−$0.23−$0.23−$0.27−$0.27−$0.25+7.8%1 up · 0 down

How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.

OCGN earnings surprises

Reported EPSEstimate

Reported EPS vs the consensus estimate for the last 12 quarters; OCGN beat in 8 of 12.

What analysts expect from OCGN

6 analysts cover Ocugen; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.17, 1,459.8% above the latest close of $0.78. Analysts expect earnings of −$0.24 per share for 2026, −2.9% from a year earlier. For 2027 the average estimate is −$0.25 per share on revenue of $5.5 million. Ocugen beat the EPS estimate in 8 of the last 12 quarters.

Related: OCGN income statement, OCGN key metrics, OCGN chart. See the OCGN stock overview for the latest quote and news.

OCGN forecast FAQ

What is Ocugen's price target?

The average analyst price target for Ocugen is $12.17, 1,459.8% above the latest close of $0.78.

Is Ocugen a buy, hold or sell?

Of 6 analysts covering Ocugen, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.

What is Ocugen's EPS forecast?

Analysts forecast −$0.24 per share for 2026 (range −$0.27 to −$0.18); for 2027 the estimate is −$0.25.

What is Ocugen's revenue forecast?

The average revenue estimate for 2026 is $5.0 million, growth of 12.3%; for 2027 it is $5.5 million.

When does Ocugen report earnings?

Ocugen is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.06.

Does Ocugen usually beat earnings estimates?

Ocugen reported EPS at or above the analyst estimate in 8 of the last 12 quarters.

Biotechnology: forecast